摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloro-6-methyl-4-(pyrid-2-ylamino)pyrimidine | 912673-36-0

中文名称
——
中文别名
——
英文名称
2-chloro-6-methyl-4-(pyrid-2-ylamino)pyrimidine
英文别名
2-Chloro-6-methyl-4-(pyrid-2-ylamino)pyrimidine;2-chloro-6-methyl-N-pyridin-2-ylpyrimidin-4-amine
2-chloro-6-methyl-4-(pyrid-2-ylamino)pyrimidine化学式
CAS
912673-36-0
化学式
C10H9ClN4
mdl
——
分子量
220.661
InChiKey
NMBBEQNXVOVJAN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    50.7
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • 4-(Pyrid-2-Yl) Amino Substituted Pyrimidine as Protein Kinase Inhibitors
    申请人:Thomas Andrew Peter
    公开号:US20080171742A1
    公开(公告)日:2008-07-17
    A compound of formula (I): wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm-blooded animal such as man.
    一种化合物,其化学式为(I):其中取代基在文本中定义,用于抑制温血动物(如人)中类胰岛素生长因子1受体的活性。
  • C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses
    申请人:Genentech, Inc.
    公开号:US20160046608A1
    公开(公告)日:2016-02-18
    The present invention provides for pyrimidine compounds of Formula I-I and embodiments thereof In Formula I-I in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m, n and the “het” ring are as described herein. Also provided are pharmaceutical compositions comprising compounds of Formula I and methods of using such compounds and compositions.
    本发明提供了式I-I的嘧啶化合物及其具体实施例。式I-I中,R1、R2、R3、R4、R5、R6、m、n和“het”环如本文所述。还提供了包含式I化合物的药物组合物以及使用这些化合物和组合物的方法。
  • Hepatitis B viral assembly effectors
    申请人:Indiana University Research and Technology Corporation
    公开号:US10273228B2
    公开(公告)日:2019-04-30
    Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
    本研究公开了对乙型肝炎病毒(HBV)感染有治疗作用的新型组装效应化合物。本文所述的组装效应分子可导致病毒组装缺陷,还可影响与慢性 HBV 感染相关的其他病毒活动。还公开了合成所公开化合物的工艺、通过服用所公开化合物治疗 HBV 的方法,以及这些化合物在制造抗 HBV 药物中的用途。
  • 4-(PYRID-2-YL) AMINO SUBSTITUTED PYRIMIDINE AS PROTEIN KINASE INHIBITORS
    申请人:AstraZeneca AB
    公开号:EP1871771A1
    公开(公告)日:2008-01-02
  • HEPATITIS B VIRAL ASSEMBLY EFFECTORS
    申请人:Indiana University Research and Technology Corporation
    公开号:US20180099952A1
    公开(公告)日:2018-04-12
    Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
查看更多